Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Browse the high quality scientific and educational content from the ESMO Congress 2022
Update your knowledge on novel immune-oncology strategies, biomarkers and more!
Join the experts developing and implementing the ESMO Guidelines and submit your questions in this real-time interaction
Come back to the excitement of an in-person congress experience by signing up today for ESMO Asia 2022, the leading platform in Asia-Pacific for the presentation of the latest advancements in the field of oncology.
Present your research at the leading congress on phase I oncology trials
Register now for ESMO Sarcoma & Rare Cancers 2023, a unique occasion for the global rare cancers community to network and discover the latest breakthroughs in the field.
Online application is open until 30 September 2022
Online application is open until 30 September 2022
Now on-demand. Take the CME test, expand your knowledge in this tumour type and get 2 ESMO-MORA category 1 points
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Two new indications concern the treatment of paediatric patients with ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumour
It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
New indication concerns the treatment of patients with diffuse large cell lymphoma and high-grade B-cell lymphoma
Findings from an assessment of predictive value of RNF43 status in patients with BRAFV600E-mutated metastatic colorectal cancer
New indication concerns treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy
Results of the largest study of preoperative immune checkpoint inhibitor monotherapy in patients with early-stage non-small cell lung cancer to date
ESMO President, Solange Peters, was invited by the WHO Regional Director for Europe, Hans Kluge, to provide an ESMO Statement on the resolution of the ‘Roadmap to accelerate the elimination of cervical cancer as a public health problem in the WHO European Region 2022–2030’
ESMO, together with 28 other organisations, endorsed a joint statement supporting the resolution on the ‘Regional digital health action plan for the WHO European Region’
ESMO, together with other organisations, endorsed a joint statement on the ‘Implementation of the Action Plan for the Prevention and Control of Noncommunicable Diseases in the WHO European Region 2016–2025: Progress report’
Two new indications concern the treatment of paediatric patients with ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumour
It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
New indication concerns the treatment of patients with diffuse large cell lymphoma and high-grade B-cell lymphoma
Findings from an assessment of predictive value of RNF43 status in patients with BRAFV600E-mutated metastatic colorectal cancer
New indication concerns treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy
Results of the largest study of preoperative immune checkpoint inhibitor monotherapy in patients with early-stage non-small cell lung cancer to date
Evidence for efficacy is based on the results from the iMAGINE study
Evidence for efficacy is based on the results from the TOPAZ-1 study
Evidence for efficacy was evaluated in FIGHT-203 study
Results from the CodeBreaK 200 trial represent an improvement for a difficult-to-treat patient population
Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit
Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet
Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity
Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies
The optimal chemotherapy regimen in this setting is not well-defined
In the OCLURANDOM trial, progression-free survival was longer in patients receiving lutetium-octreotate versus sunitinib
Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients
Results of a small phase II trial may open up a new option for some patients with leukoplakia, but toxicity of immunotherapy is high and questions remain about its utility in clinical practice
Cancer doctors, care providers and payers need to get ready for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment
A novel treatment strategy with personalised cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma
Significant improvement in progression free survival and response rate combined with reduced symptoms and better quality of life are reported as outcomes of a new treatment approach for patients with desmoid tumours
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies
Sustainability will be at the heart of many discussions at the ESMO Congress 2022 , as illustrated by the new results and initiatives spanning cancer prevention, early detection and treatment that were announced today during the opening press conference
ESMO and EONS announce the launch of the ground-breaking, Europe-wide “Cancer Prevention Across Europe” campaign (PrEvCan) aimed at reducing the burden of cancer
The ESMO Congress 2022 will be held in person in Paris and virtually between 9-13 September 2022.
The ESMO World Congress on Gastrointestinal Cancer, the annual event dedicated to the presentation and discussion of new findings in GI cancer treatment, research and care, will be held as a fully onsite event in Barcelona, Spain, from 29 June to 2 July 2022.
Data from two large cancer centres in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care.
ESMO has announced today the winners of the 2022 ESMO Society Awards.
ESMO has announced today the results of its Executive Board elections following the closure of the voting system on Monday 27 June 2022.
ESMO has announced today that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
In light of the challenging situation in Prague due to the ongoing arrival of refugees from Ukraine
ESMO expresses profound sadness about the unfolding tragedy in Ukraine and the suffering of people
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
The 2022 ESMO Heine H. Hansen Award is conferred on Fred R. Hirsch for his lifelong outstanding contribution to lung cancer research
Who will be the next ESMO Awardees? Submit your nominations before 9 March.
Developed by the ESMO Precision Medicine Working Group, they provide guidance to medical oncologists on the use of circulating tumour DNA assays in clinical practice
The role of polygenic scores for stratified cancer prevention, and the genetic determinants for PSA levels to improve cancer screening utility will be debated during the sixth instalment in the World Cancer Report Updates webinar series.
This year, World Cancer Day is launching #CloseTheCareGap, a three-year campaign aiming to promote awareness, collaboration, and action for a more equitable future in cancer care.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on
With modest progress being made in the gender balance of the oncology field in recent years, women continue to be underrepresented in leadership positions despite making up an increasing proportion of the oncology workforce.
From ESMO Congress 2022:
Patients without evidence of disease after stage IV melanoma surgery or radiotherapy have significantly better overall survival with adjuvant use of nivolumab plus ipilimumab versus placebo
A focus on the latest research in targeting cancer microbiome
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Switzerland
Republic of Singapore
Netherlands
Switzerland
Australia
Spain
Hungary
Switzerland
Republic of Singapore
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2022 will be held on Saturday 10 September (17:30-20:00 CEST) during the ESMO Congress 2022 in Paris, France.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
